
Researchers at the University of Nottingham have developed and validated a novel, CDI assay, enabling treatment stratification for patients with acute Clostridium difficile infection. Utilising a number of biomarkers, two prediction tools have been validated. Firstly, the severity of CDI can be predicted and categorised as either Mild or Severe. In addition, a 30- day mortality prediction tool using a number of CDI related toxins and proteins has been developed.
Clostridium difficile (CDI) is the leading worldwide infective cause of hospital-acquired and antibiotic-associated diarrhoea, imposing a considerable financial burden on health service providers. In Europe alone, the annual estimated costs for the management of CDI amount to €3Billion. Infection causes a spectrum of clinical presentations, ranging from an asymptomatic carrier state to severe fulminant coli s and death. Management of this infection is complicated due to antimicrobial resistance, recurring infections, and strikingly the inability to reliably differentiate between acute infection and asymptomatic or symptomatic carrier states.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.